ARGX-113-2301 (UplighTED) - Clinical Trial
What is the Purpose of this Study?
In this study, people will be randomly chosen to get either a medicine called efgartigimod or a placebo. A placebo looks like the real medicine but does not have any medicine in it. It is used to help compare results.
There is a 67% chance of getting efgartigimod and a 33% chance of getting the placebo. That means twice as many people will get the real medicine.
The study will last about 1 to 2 years, depending on how each person reacts to the medicine. People will need to visit the study clinic up to 20 times for tests and check-ups.
Thyroid Eye Disease
Who Can Participate in the Study?
People in this study must:
- Be 18 years old or older.
- Have active Thyroid Eye Disease (TED) that is linked to Graves' disease or Hashimoto's thyroiditis.
- Not have had radiation or surgery to treat TED before.
What is Involved?
This study is trying to find out if a new medicine called efgartigimod can help people who have Thyroid Eye Disease, or TED. The study also wants to make sure the medicine is safe for people to use.